HIV-1 outbreak among injecting drug users in Greece, 2011: A preliminary report

Eurosurveillance

Volumn 16, Issue 36, 2011, Pages

  Paraskevis, D ^a   Nikolopoulos, G ^b   Tsiara, C ^b   Paraskeva, D ^b   Antoniadou, A ^a   Lazanas, M ^c   Gargalianos, P ^d   Psychogiou, M ^a   Malliori, M ^e   Kremastinou, J ^b   Hatzakis, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

^c RED CROSS HOSPITAL   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e Organization Against Drugs (OKANA)   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG USE; EPIDEMIC; EPIDEMIOLOGICAL DATA; GREECE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PREVALENCE; VIRUS TRANSMISSION;

EID: 80052774224     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.16.36.19962-en     Document Type: Article

References (19)

1. Nikolopoulos G, Paraskevis D, Hatzakis A. HIV epidemiology in Greece. Future Microbiol. 2008; 3(5):507-16.
2. Hellenic Center for Disease Control and Prevention (HCDCP). HIV/AIDS Surveillance Report in Greece, 31-10-2010. (Issue 25). HCDCP: Athens. 2010. Available from: http://www.hivaids.gr/pliroforisi/epidiomiologiko2010.pdf
3. Swofford DL. PAUP. Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4. Sinauer Associates. Sunderland, Massachusetts. 1998.
4. Paraskevis D, Magiorkinis E, Magiorkinis G, Sypsa V, Paparizos V, Lazanas M, et al. Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J Infect Dis. 2007;196(8):1167-76.
5. Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, et al. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology. 2009;6:49.
6. Paraskevis D M, Zavitsanou E, Detsika A, Magiorkinis M, Papa G, Beloukas A, et al for the multicenter study of HIV heterogeneity (2010). Molecular typing of the HIV-1 networks through a nationwide study in Greece: predominance of subtype A over B spreading among the natives. 10th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases Amsterdam. 3-5 Nov 2010.
7. Delgado E, Thomson MM, Villahermosa ML, Sierra M, Ocampo A, Miralles C, et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr. 2002;29(5):536-43.
8. Bobkov A, Cheingsong-Popov R, Selimova L, Ladnaya N, Kazennova E, Kravchenko A, et al. An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses. 1997;13(14):1195-201.
9. Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempová D, Griffiths P. HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill. 2008;13(50):pii=19067. Available from: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=19067
10. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2010 Annual report on the state of the drugs problem in Europe. Lisbon: EMCDDA. Nov 2010. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf
11. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008;70(5):606-11.
12. Friedman SR, Rossi D, Braine N. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20(3):283-91.
13. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733-45.
14. Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010;21(2):122-4.
15. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285-301.
16. Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449-53.
17. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268-84.
18. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
19. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105(5):907-13.